These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Gene therapy on trial. Marshall E Science; 2000 May; 288(5468):951-7. PubMed ID: 10841710 [No Abstract] [Full Text] [Related]
45. The NIH "Points to Consider" and the limits of human gene therapy. Juengst ET Hum Gene Ther; 1990; 1(4):425-33. PubMed ID: 2078585 [TBL] [Abstract][Full Text] [Related]
46. Public oversight is necessary if human gene therapy is to progress. Zallen DT Hum Gene Ther; 1996 May; 7(7):795-7. PubMed ID: 8860831 [No Abstract] [Full Text] [Related]
47. The ethics of human gene therapy. Walters L Nature; 1986 Mar 20-26; 320(6059):225-7. PubMed ID: 3457268 [TBL] [Abstract][Full Text] [Related]
48. Human gene therapy: ethics and public policy. Walters L Hum Gene Ther; 1991; 2(2):115-22. PubMed ID: 1911932 [TBL] [Abstract][Full Text] [Related]
50. The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. Anderson WF; Blaese RM; Culver K Hum Gene Ther; 1990; 1(3):331-62. PubMed ID: 11642817 [No Abstract] [Full Text] [Related]
51. Recombinant DNA Advisory Committee, Human Gene Therapy Subcommittee. Minutes of Meeting, April 24, 1987. Recomb DNA Tech Bull; 1987 Jun; 10(2):51-8. PubMed ID: 3478767 [No Abstract] [Full Text] [Related]
52. The N2-TIL human gene transfer clinical protocol. Hum Gene Ther; 1990; 1(1):73-92. PubMed ID: 2081189 [No Abstract] [Full Text] [Related]
53. Gene therapy: research in public. Culliton BJ Science; 1985 Feb; 227(4686):493-6. PubMed ID: 3880924 [TBL] [Abstract][Full Text] [Related]
58. Overregulation is an unnecessary hindrance to human gene therapy. Miller HI Hum Gene Ther; 1995 Nov; 6(11):1361-2. PubMed ID: 8573609 [No Abstract] [Full Text] [Related]
59. Varmus proposes to scrap the RAC. Marshall E Science; 1996 May; 272(5264):945. PubMed ID: 8638134 [No Abstract] [Full Text] [Related]